

Printed: 21-09-2004

CLMSPAMD


DT12 Rec'd PCT/PTO 12 JAN 2005
EPO - DG 1

15 09 2004

CLAIMS

(68)

1. Use of an estrogenic component selected from the group consisting of: substances represented by the following formula



in which formula R_1 , R_2 , R_3 , R_4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms;

precursors capable of liberating a substance according to the aforementioned formula when used in the present method, which precursors are derivatives of the present estrogen substances, wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranyl; or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue; and mixtures of one or more of the aforementioned substances and/or precursors;

in the manufacture of a pharmaceutical composition for use in a method of treating or preventing estrogen-sensitive tumours in a mammal, said estrogen-sensitive tumours being selected from the group consisting of breast cancer and uterine cancer, ovarian cancer, endometriosis, uterine fibroids, benign prostatic hyperplasia and melanoma; and said method comprising the administration of a therapeutically effective amount of the estrogenic component to said mammal and not comprising administration of a GnRH composition.

2. Use of an estrogenic component as defined in claim 1 in the manufacture of a pharmaceutical composition for use in a method of treating or preventing estrogen-sensitive

Printed: 21-09-2004

OLMSPAMD

NL0300513

tumours in a mammal, said estrogen-sensitive tumours being selected from the group consisting of breast cancer and uterine cancer, ovarian cancer, endometriosis, uterine fibroids, benign prostatic hyperplasia and melanoma; and said method comprising the administration to said mammal of a therapeutically effective amount of the estrogenic component in combination with an aromatase inhibitor.

3. Use of an estrogenic component as defined in claim 1 in the manufacture of a pharmaceutical composition for use in a method of treating estrogen-sensitive tumours in a mammal, said estrogen-sensitive tumours being selected from the group consisting of breast cancer and uterine cancer, ovarian cancer, endometriosis, uterine fibroids, benign prostatic hyperplasia and melanoma; and said method comprising the administration of a therapeutically effective amount of the estrogenic component to said mammal.

2. Use according to any one of claims 1-3, wherein no more than 3 of R₁, R₂, R₃, R₄ are hydrogen atoms;

3. Use according to any one of claims 1-4 or 2, wherein R₃ represents a hydroxyl group or an alkoxy group.

4-6. Use according to any one of claims 1-53, wherein at least 3 of the groups R₁, R₂, R₃ and R₄ represent hydrogen atoms.

5. Use according to any one of claims 1-4, wherein the precursors capable of liberating the estrogenic substance are derivatives of the present estrogen substances, wherein the hydrogen atoms of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranyl; or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue.

6-7. Use according to any one of claims 1-65, wherein the method comprises the uninterrupted administration of the estrogenic component during a period of at least 5 days, preferably of at least 30 days.

Printed: 21-09-2004

CLMSPAMD

NL0300513

7-8. Use according to any one of claims 1-76, wherein the method comprises oral, transdermal, intravenous or subcutaneous administration of the estrogenic component.

8-9. Use according to claim 87, wherein the method comprises oral administration.

9-10. Use according to any one of claims 1-98, wherein the estrogenic component is administered in an amount of at least 1 µg per kg of bodyweight per day, preferably of at least 5 µg per kg of bodyweight per day.

10 10. Use according to any one of claims 1-9, wherein the estrogen-sensitive tumours are selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, endometriosis, uterine fibroids, benign prostatic hyperplasia and melanoma.

11. Use according to any one of claims 1-10, wherein the estrogen-sensitive tumours are selected from the group consisting of breast cancer and uterine cancer.

12. Use according to any one of claims 1-11, wherein the method comprises co-administration of an estrogen suppressant in an amount effective to suppress the endogenous estrogen production, wherein said estrogen suppressant is selected from the group consisting of progestogens, GnRH analogues, aromatase inhibitors, cyclo-oxygenase 2 (COX-2) inhibitors, 17β-hydroxysteroid dehydrogenase type 1 inhibitors and combinations thereof.

13-12. Use according to claim 211, wherein the aromatase inhibitor/estrogen suppressant is co-administered in an effective amount to suppress blood serum 17β-estradiol level to below 10 pg/ml, more preferably to below 5 pg/ml, most preferably to below 1 pg/ml

14. Use according to claim 11 or 12, wherein the method comprises co-administration of a progestogen

15-13. Use according to claim 1 or 31 or 12, wherein the method comprises co-administration of an aromatase inhibitor.


16-14. A pharmaceutical composition containing:

Printed: 21-09-2004

GLMSPAMD

NL0300513

- a. at least 0.01 mg of an ~~estrogen suppressant selected from the group consisting of~~
aromatase inhibitors, GnRH analogues and combinations thereof;
- b. at least 0.05 mg of an estrogenic component selected from the group consisting of:
substances represented by the following formula



in which formula R_1 , R_2 , R_3 , R_4 independently are a hydrogen atom, a hydroxyl group
or an alkoxy group with 1-5 carbon atoms;

precursors capable of liberating a substance according to the aforementioned formula
when used in the present method, which precursors are derivatives of the present estrogen
substances, wherein the hydrogen atom of at least one of the hydroxyl groups has been
substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid
of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranyl; or a straight or branched
chain glycosidic residue containing 1-20 glycosidic units per residue; and mixtures of one
or more of the aforementioned substances and/or precursors; and

- c. pharmaceutically acceptable excipient.

~~17.15.~~ The pharmaceutical composition according to claim ~~146~~, wherein no more than 3 of
 R_1 , R_2 , R_3 , R_4 are hydrogen atoms.

~~18.16.~~ The pharmaceutical composition according to claim ~~146~~ or ~~157~~, wherein R_3 represents
a hydroxyl group or an alkoxy group.

Printed: 21-09-2004

CLMSPAMD

NL03005113

~~19-17.~~ The pharmaceutical composition according to any one of claims ~~146-168~~, wherein at least 3 of the groups R_1 , R_2 , R_3 and R_4 represent hydrogen atoms.

~~18.~~ The pharmaceutical composition according to any one of claims ~~16-19~~, wherein the precursors capable of liberating the estrogenic substance are derivatives of the present estrogen substances, wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; tetrahydrofuran-yl; tetrahydropyran-yl; or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue.

~~21-18.~~ The pharmaceutical composition according to any one of claims ~~146-1720~~, wherein the composition contains aromatase inhibitor in an amount equivalent to an oral dosage of at least 0.05 mg anastrozole.

~~22-19.~~ A drug delivery system comprising a pharmaceutical composition according to any one of claims ~~136-217~~, said drug delivery system being selected from the group consisting of an oral dosage unit; an injectable fluid; a suppository; a pessary; a gel; and a cream.

~~23-20.~~ A pharmaceutical kit comprising one or more dosage units containing at least 0.05 mg of the estrogenic component as defined in claim 1 and a pharmaceutically acceptable excipient; and one or more dosage units containing at least 0.01 mg of an estrogen suppressant selected from the group consisting of GnRH analogues, aromatase inhibitors, cyclo-oxygenase 2 (COX-2) inhibitors, 17 β -hydroxysteroid dehydrogenase type 1 inhibitors and combinations thereof, and a pharmaceutically acceptable excipient.

~~24-21.~~ The pharmaceutical kit according to claim ~~2023~~, wherein the dosage units are oral dosage units.